In a real-world study in Germany, Givlaari (givosiran) was found to effectively prevent severe acute attacks and reduce chronic health burden in people with acute intermittent porphyria (AIP) — patients who are commonly excluded from porphyria studies and who would have been ineligible to participate in the…
Undiagnosed hereditary hemochromatosis in a 34-year old woman played a key role in her developing porphyria cutanea tarda (PCT), according to a case report. The woman was treated with therapeutic phlebotomy, or bloodletting, to remove excess iron from the blood, which significantly eased her symptoms. Hereditary hemochromatosis is a…
An online health education program significantly reduced acute attacks, boosted mental health, and improved quality of life for people with acute intermittent porphyria (AIP), a study reported. The researchers said the findings “hold important clinical significance for broader application.” The study, “Effects of internet-based health education on patients…
Abdominal pain accompanied by nausea and vomiting, and a red-brownish urine could be indicative of acute hepatic porphyria (AHP), a case report suggests. The symptoms’ presence means physicians should “consider the rare diagnosis of porphyria so that appropriate and timely treatment can be rendered and genetic screening of family…
The production of bile acids, which are molecules made by the liver to help with digestion, is dysregulated in people with acute intermittent porphyria (AIP), according to a recent study. Findings suggest the levels of certain bile acids may serve as an objective biological marker of AIP severity, and…
The incidence of liver cancer is highest among adults with acute hepatic porphyrias (AHPs) who are older, female, symptomatic, and diagnosed with acute intermittent porphyria (AIP), one of the most common AHP subtypes. Those are the results of a pooled analysis of published studies conducted by a team of…
Note: This story was updated Nov. 4, 2024, to correct that Givlaari was given via subcutaneous injections, not through infusions. Upper body pain and muscle weakness led to a misdiagnosis of Parsonage-Turner syndrome (PTS) for a woman in France who was later found to have acute…
Vitamin D plays a crucial role in maintaining and enhancing bone mineral density in people with erythropoietic protoporphyria (EPP), according to a study from the Netherlands. EPP patients in the study had high prevalence of osteopenia, or lower-than-normal bone density, and osteoporosis, a more severe form of bone loss.
Note: This story was updated Oct. 25, 2024, to correct that hemin was used during this study to treat porphyria attacks. Long-term use of the approved therapy Givlaari (givosiran) safely led to sustained reductions in porphyria attacks, and in the need for medications to treat such attacks, in…
The United Porphyrias Association (UPA) has received a five-year grant from the Chan Zuckerberg Initiative Rare As One Project to support efforts including advancing progress on the diagnosis, research, and treatment of porphyria. The association said the grant will “significantly enhance UPA’s ability to build a comprehensive…
Get regular updates to your inbox.